Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

Injection the day before surgery of 90 mg of Lanreotide LP sub-cutaneously or placebo. Evaluation of the lymphorrhea in the 2 arms of the study

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Limoges
• Collaborator: Ipsen
• Treatments: Angiopeptin; Lanreotide; Somatostatin

Criteria

Inclusion Criteria:

• Adult patient (> 18 years),

• Patient undergoing an axillary lymphadenectomy for breast cancer

• Patient giving her agreement after being informed

Exclusion Criteria:

• Patients that don't understand the trial

• Type 2 diabetic patients

• Cyclosporine treatment

• Biliary lithiasis

• Pregnancy or breast feeding

• Allergic reaction to Lanréotide or same class treatments

• Patient included in another trial within the last 30 days